BEUDAMED
    FDA PMA FDA Class 3 Approved 🇺🇸 United States

    Stimulator, Hypoglossal Nerve, Implanted, Apnea

    PMA: P130008 · Supplement: S093 · Decision Dec 16, 2022
    View on FDA
    Classifications
    1
    FEI Numbers
    10
    Registration Numbers
    10

    Basic Information

    Device Name
    Stimulator, Hypoglossal Nerve, Implanted, Apnea
    Trade Name
    Inspire II Upper Airway Stimulator
    PMA Number
    P130008
    Supplement Number
    S093
    Device Class
    FDA Class 3
    Product Code
    MNQ
    Generic Name
    Stimulator, hypoglossal nerve, implanted, apnea
    Medical Specialty
    Unknown
    Advisory Committee
    Anesthesiology
    Decision
    Approved
    Decision Code
    APPR
    Decision Date
    December 16, 2022
    Date Received
    November 18, 2022
    Supplement Type
    Normal 180 Day Track No User Fee
    Supplement Reason
    Postapproval Study Protocol
    Expedited Review
    N

    Advisory Committee Statement

    Approval for the Inspire® Upper Airway Stimulation (UAS). The device is indicated for use to treat a subset of patients with moderate to severe obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI] of greater than or equal to 15 and less than or equal to 65). Inspire® UAS is used in adult patients 22 years of age and older who have been confirmed to fail or cannot tolerate positive airway pressure (PAP) treatments (such as continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BPAP] machines) and who do not have a complete concentric collapse at the soft palate level.PAP failure is defined as an inability to eliminate OSA (AHI of greater than 15 despite PAP usage), and PAP intolerance is defined as:1) Inability to use PAP (greater than 5 nights per week of usage; usage defined as greater than 4 hours of use per night); or2) Unwillingness to use PAP (for example, a patient returns the PAP system after attempting to use it).Inspire® UAS is also indicated for use in patients between the ages of 18 and 21with moderate to severe OSA (15?AHI?65) who:1) Do not have complete concentric collapse at the soft palate level;2) Are contraindicated for, or not effectively treated by, adenotonsillectomy;3) Have been confirmed to fail, or cannot tolerate, PAP therapy despite attempts to improve compliance; and4) Have followed standard of care in considering all other alternative/adjunct therapies.

    Classifications

    This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

    Product Code Device Name
    MNQ Stimulator, Hypoglossal Nerve, Implanted, Apnea